Willaim C. Bertrand, Jr. net worth and biography

Willaim Bertrand, Jr. Biography and Net Worth

William C. Bertrand Jr., Esq., J.D. serves as Chief Operating Officer of the Company. Mr. Bertrand's prior experience includes a 12 year tenure at MedImmune, where he served as its first General Counsel and Chief Compliance Officer, along with holding a variety of operational and corporate strategy roles. He has also formerly served as Executive Vice President, General Counsel for Infinity Pharmaceuticals, Inc., and as Senior Vice President, Acting Chief Operating Officer and General Counsel for Salix Pharmaceuticals, where he remained as General Manager to help finalize the integration of the company's $14 billion acquisition by Valeant Pharmaceuticals in April 2015. He is currently a member of the board of directors of Ardelyx, Inc. (Nasdaq:ARDX). Mr. Bertrand received a J.D. from the University of Wisconsin and a B.S. in biology from Wayne State University.

What is Willaim C. Bertrand, Jr.'s net worth?: The estimated net worth of Willaim C. Bertrand, Jr. is at least $4,668.19 as of January 16th, 2024. Mr. Bertrand, Jr. owns 7,023 shares of Adaptimmune Therapeutics stock worth more than $4,668 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Bertrand, Jr. may own. Learn More about Willaim C. Bertrand, Jr.'s net worth.
How do I contact Willaim C. Bertrand, Jr.?: The corporate mailing address for Mr. Bertrand, Jr. and other Adaptimmune Therapeutics executives is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. Adaptimmune Therapeutics can also be reached via phone at 441235430000 and via email at [email protected]. Learn More on Willaim C. Bertrand, Jr.'s contact information.
Has Willaim C. Bertrand, Jr. been buying or selling shares of Adaptimmune Therapeutics?: Willaim C. Bertrand, Jr. has not been actively trading shares of Adaptimmune Therapeutics during the past quarter. Most recently, William C. Bertrand, Jr. sold 4,681 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $0.79, for a transaction totalling $3,697.99. Following the completion of the sale, the chief operating officer now directly owns 7,023 shares of the company's stock, valued at $5,548.17. Learn More on Willaim C. Bertrand, Jr.'s trading history.
Who are Adaptimmune Therapeutics' active insiders?: Adaptimmune Therapeutics' insider roster includes Willaim Bertrand, Jr. (COO), John Lunger (Insider), Elliot Norry (Insider), and Adrian Rawcliffe (CEO). Learn More on Adaptimmune Therapeutics' active insiders.
Are insiders buying or selling shares of Adaptimmune Therapeutics?: During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 61,977 shares worth more than $53,507.07. The most recent insider tranaction occured on June, 18th when insider Cintia Piccina sold 24,531 shares worth more than $22,813.83. Insiders at Adaptimmune Therapeutics own 12.4% of the company. Learn More about insider trades at Adaptimmune Therapeutics.
Information on this page was last updated on 6/18/2024.

Willaim C. Bertrand, Jr. Insider Trading History at Adaptimmune Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	4,681	$0.79	$3,697.99	7,023
1/12/2024	Sell	5,220	$0.85	$4,437.00	7,874
1/12/2023	Sell	4,973	$1.71	$8,503.83	8,121
1/4/2023	Sell	3,584	$1.69	$6,056.96	5,781
1/18/2022	Sell	4,368	$3.19	$13,933.92
1/11/2022	Sell	3,770	$3.56	$13,421.20
1/4/2022	Sell	3,490	$4.06	$14,169.40
1/12/2021	Sell	2,234	$6.15	$13,739.10
1/4/2021	Sell	3,499	$5.33	$18,649.67
12/14/2020	Buy	207,000	$0.69	$142,830.00
1/14/2020	Sell	2,397	$5.13	$12,296.61
1/6/2020	Sell	3,731	$1.20	$4,477.20
1/14/2019	Sell	2,271	$5.37	$12,195.27

Willaim C. Bertrand, Jr. Buying and Selling Activity at Adaptimmune Therapeutics

Adaptimmune Therapeutics Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $0.66

$0.64

$0.71

50 Day Range

MA: $0.85

$0.59

$1.11

2 Week Range

Now: $0.66

$0.42

$2.05

Volume

4,158,925 shs

Average Volume

1,733,154 shs

Market Capitalization

$170.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late